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Abstract
Chromosomal abnormalities includes1) abnormalities in number of chromo-
somes which are known as aneuploidies and 2) structural defects like translocations
and deletions. In this we will discuss about Aneuploidies The incidence of Aneu-
ploidy is around one in 200 live births. Aneuploidy increases with advancing
maternal age. Fetal aneuploidy has been associated with significant pregnancy
complications such as growth restriction, congenital malformations and perinatal
deaths. Several Major developments are happened in prenatal screening of Aneu-
ploidy especially the introduction of first trimester screen with Nuchal thickness
and fetal cell free DNA in maternal plasma and identification of ultrasound markers
and biochemical screening in second trimester. In this chapter we will discuss about
what are trisomies, why “Down syndrome” is important to detect prenatally, his-
tory of “Down syndrome”, advances in screening methods biochemical as well as
sonographic markers in first and second trimester and the criteria to get those
markers. What are the features of trisomy 21, trisomy18 and trisomy13.
Keywords: Aneuploidies 1, “Down syndrome” 2, ultrasound markers 3, Nuchal
translucency 4
1. Introduction
Aneuploidies are Trisomy21(“Down syndrome”, T21), Trisomy18 (Edward syn-
drome, T18), trisomy13 (Patau syndrome, T13), monosomy (turner syndrome,
monosomy) and triploidy. “Down syndrome” is more focused than other aneu-
ploidy due to Trisomy 13 and 18 are lethal, do not have very long-term conse-
quences, and almost all cases have major structural abnormalities and can be
identified on the basis of these features. Where as in T21 the ultrasound and
laboratory findings are subtle and nonspecific. Special effort has to be made to
identify these nonspecific features and analyse their importance. Identification of
T21 is based on these subtle abnormal structures i.e., ultrasound markers and
abnormal biochemistry (low PAPP-A and raised β-HCG). The abortion rate in
monosomy X is 98% and Edwards is 86% whereas “Down syndrome” is only 30%.
Not only this Downs is the commonest congenital cause of mental disability with
long life span and need life-long family support. The incidence is 1in 800 pregnan-
cies. Downs can lead to considerable ill health, although some individual may have
only mild problems and can lead relatively normal lives. Having baby with “Down
syndrome” is likely to have significant impact on family life. There is currently no
known cure. A significant number of parents would opt for terminating such a
pregnancy or if they want to continue prior information would benefit for
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preparing for such a baby. Downs occur due to non-disjunction type (Errors in
meiosis). Translocation type and mosaic type which is rare.
2. History
In 1862 & 1887 Langdon Down noted that common characteristics of patients
with trisomy 21 are skin deficient in elasticity, giving the impression of being too
large for the body, and face is flat, broad and destitute of prominence. The cheeks
are roundish and extended laterally. The eyes are obliquely placed, and internal
canthi more than normally distanced from one another. The palpebral fissure is
very narrow. The tongue is long, thick and much roughened. The nose is small. In
1987 B Benacerraf [1], told that this loose skin can be seen in mid trimester scan at
20 weeks as a thickening of skin at the back of neck in axial view of skull in trans
cerebellar plane which was defined as nuchal fold. After 5 years it was realized that
the excess skin of individuals with Down’s syndrome can be visualized by ultraso-
nography as increased nuchal translucency in the third month of intrauterine life
[2]. About 75% of trisomy 21 fetuses have increased nuchal translucency (NT) and
60–70% have absent nasal bone.
2.1 History of screening methods
Aneuploidy increases with advancing maternal age. So, increasing the maternal
age increases the risk. in the early 1970s, the screening was based only on the
association with advanced maternal age. In late 1980s not only maternal age but also
found that the concentration of various fetoplacental products in the maternal
circulation has taken into account for screening. At 16 weeks of gestation the
median maternal serum concentrations of alpha-fetoprotein (AFP), un-conjugated
estriol (μE3), human chorionic gonadotropin (HCG) (free- β and total) and inhibin-
A in aneuploidy are sufficiently different from normal to allow the use of combina-
tions or some or all of these substances to select high risk group. This method is
more effective than maternal age alone. It can identify about 60–70% of the fetuses
with T21. In1990s, screening by a combination of maternal age and fetal NT thick-
ness at 11–13 + 6 weeks of gestation was introduced. This method shown to identify
about 75–80% of affected fetuses for a screen-positive rate of about 5%. There by,
Figure 1.
Aneuploidy screening Approach: observed Detection rates.
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maternal age was combined with fetal NT and maternal serum biochemistry (free β-
HCG and PAPP-A) in the first-trimester to identify about 85–90% of affected
fetuses. In 2001, it was found that 60–70% Trisomy 21 fetuses were associated with
non-visualized nasal bone. Inclusion of nasal bone and the other ultrasound markers
to NT and biochemistry for the screening procedure increase the detection rate in to
more than 95% in first trimester with a screen positive rate of 2.5% (Figure 1).
Furthermore, introduction of one-stop clinics for assessment of risk (OSCAR)
which is a new method of biochemical testing, where with-in 30 min of taking
blood sample, made it possible to assess the risk [3, 4].
3. Type of screening tests
“Down syndrome” can be diagnosed during pregnancy. Diagnostic tests are inva-
sive and have an inherent miscarriage rate, however, small they are also expensive.
Screening tests can identify a large number of patients who would benefit from
diagnostic testing thus reducing risks and costs. Screening tests by definition, cannot
identify all accepted pregnancies. First trimester screening is far more effective than
later screening. Aneuploidy screening should be offered to all the pregnant women.
Screening tests that are performed in the first and second trimesters include
integrated, sequential and contingent screening. The basic types are 1) first trimester
combined screening the components in this are Nuchal translucency (NT), PAPP-A
and β-HCG. The detection rate is 85–95%. If you add nasal bone and other ultrasound
features to this the detection rate increases 93–96%. 2) Triple test the components are
β-HCG, MS-AFP and unconjugated Estriol. The detection rate is only 60–65%. 3)
Quadruple test β-HCG, MS-AFP, unconjugated Estriol and inhibin A. the detection
rate is 70–75%. 4) Penta screen includes hyper glycosylated HCG in addition to
quadruple test. If patient come for screening in first trimester, first trimester com-
bined screening is advised, if she comes at 14-20 weeks quadruple test, if she comes at
both first and second trimester integrated test is best for screening (Table 1).
Integrated test:-Integrate the First trimester PAPP-A, Free β-HCG and NT ana-
lyte screening followed by a second trimmester Quad screen and receives a single




Maternal age(MA) 30% 5%
First trimester
MA+ fetal nuchal translucency(NT) 75–80% 5%
MA+ serum free β-hCG and PAPP-A 60–70% 5%
MA + NT + free β-hCG and PAPP-A (combined Test) 85–95% 5%




MA + serum AFP,hCG, μE3(triple test) 60–65% 5%
MA + serum AFP,free β-hCG, μE3, inhibin A(Quadruple test) 70–75% 5%
MA + NT + PAPP-A(11-13 weeks) + quadruple test 90–94% 5%
Nicolaides KH. Screening for fetal aneuplodies at 11t013weeks.Prenat Diagn 2011;31:7–15.
Table 1.
Methods of screening and its detection rate.
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screen test result. The detection rate of this test is 90–94%. Limitations includes the
withholding of first trimester screening test results until the second trimester which
delay the management option.
Sequential screening: - these are two types one is stepwise another one is con-
tingent model. These methods were developed to maintain a high detection rate. in
step wise sequential model it can be achieved by using the combined first and
second trimester screening approach while also reporting the patients first trimester
screening test risk, which allows for earlier management options. If first trimester
test result is higher than lab derived positive screening cutoff, we can offer them the
diagnostic test or NIPT, and the screening protocol is discontinued. If the patient
has a lower risk can counseled and proceed to quad screening in the second trimes-
ter. Sequential screening has a detection rate of 91–93% with a positive screening
test result rate of 4–5% [5–7].
Contingent model classifies aneuploidy risk as high, intermediate or low on the
basis of first trimester screening test results. High risk patients are offered cell free
DNA screening or diagnostic testing with CVS and for low risk women further
screening or testing is not recommended. Only those with intermediate risk are
offered second trimester screening.
4. Method of sequential screening
Every woman has a risk that her fetus has a chromosomal abnormality.
4.1 Standard first trimester aneuploidy screening
to calculate the individual risk, the clinical information which is necessary to
take into account the background or a priori risk, depends on maternal age, weight
the ethnicity (in terms of south Asian, east Asian, south east Asian black or Cauca-
sian), IVF, number of fetuses diabetes and smoking. This information should be
combined with ultrasound information and biochemistry. Which is based on crown
rump length, NT, PAPP-A, free β-HCG. Then make calculation by a series of factors
or likelihood ratios, which depend on the results of a series of screening tests carried
out during the course of the pregnancy to determine the patient-specific risk. A
priori risk established by maternal age has been adjusted successfully by NT
screening. This has been one of the most important elements of aneuploidy screen-
ing as it resulted in a significant reduction in unnecessary invasive testing on
pregnant women with advanced maternal age. If you add rest of the ultrasound
features like nasal bone, ductus venosus and tricuspid regurgitation which can
increase the rate of detection.
4.2 Standard genetic sonogram aneuploidy screening
Genetic sonogram has been used to screen for Aneuploidy by using specific
findings. In this approach seeks major structural abnormalities and minor ultraso-
nographic soft markers. These Soft markers are minor ultrasound abnormalities,
considered as variants of normal, they do not constitute a structural defect. Pres-
ence of Soft markers are indicative of an increased age adjusted risk of an underly-
ing fetal aneuploidy or some non- chromosomal abnormalities. So, these are also a
priori risk. Detection of soft markers increase the risk for aneuploidy by constant
proportion (likelihood ratio LR). Absence of these markers lower the risk (Negative
predictive value NPV). These were decided after a meta-analysis study of second
trimester markers for trisomy21 [8], (Table 2).
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Every time a test is carried out the a priori risk ismultiplied by the likelihood ratio of
the test to calculate a new risk, which then becomes the a priori risk for the next test [9].
If a systematic second- trimester ultrasound examination demonstrates the
absence of all major defects and markers, there is a 7.7fold reduction in risk for
trisomy 21. Detection of any one of the markers during the scan should stimulate
the sonographer to look for all other markers or defects. Post-test odds for trisomy
21 is derived by multiplying the pre-test odds by the positive LR for each detected
marker and the negative LR for each marker demonstrated to be absent.
In Sequenitial screening first do the first trimester combined screening test
identify the risk based on this risk if it is high risk do the invasive procedure (CVS)
or NIPT. If there is false positive and false negetive results then you need to
combine with quadraple test and sequentially calcuate the risk as the false positive
rate is very very low.
5. Biochemical markers
First trimester markers are pregnancy associated plasma protein A (PAPP-A),
Free β Human chorianic gonadotropin (β-HCG) where as second trimester markers
are Alpha fetoprotein (AFP) Unconjugated oestriol (μE3), Total human chorianic
gonadotropin (HCG) and inhibin-A.
The PAPP-A level is low in T21 which is about half of euploid pregnancies. β-
HCG levels are double that of unaffected pregnancies. The concentrations of these
markers vary with gestational age. In first trimester PAPP-A increases and free β-
HCG decreases. In second trimester AFP and μE3 increase HCG and inhibin-A will
decreases before 17 weeks after that it may increas. The measurements of these
markers may vary between laboratories. In account of this variation the concentra-
tion of each marker is expressed as multiple of median for unaffected pregnancies
of the same gestational age.(MoM).
6. First trimester sonographic markers
provision of a high-quality first trimester screening service significantly
enhances the autonomy of pregnant women [10].
Marker LR+(95%CI) LR-(95%CI) LR isolated marker*
Intra cardiac echogenic focus 5.83(5.02–6.77) 0.80(0.75–0.86) 0.95
Ventriculomegaly 27.52(13.61–55.68) 0.94(0.91–0.98) 3.81
Increased nuchal fold 23.30(14.35–37.83) 0.80(0.74–0.85) 3.79
Echogenic bowel 11.44(9.05–14.47) 0.90(0.86–0.94) 1.65
Mild Hydronephrosis 7.63(6.11–9.51) 0.92(0.89–0.96) 1.08
Short humerus 4.81(3.49–6.62) 0.74(0.63-o.88) 0.78
Short femur 3.72(2.79–4.97) 0.80(0.73–0.88) 0.61
ARSA 21.48(11.48–40.19) 0.71(0.57–0.88) 3.94
Absent or hypoplastic nasal bone 23.27(14.23–38.06) 0.46(0.36–0.58) 6.58
Table 2.
Meta-analysis of 2nd trimester markers for trisomy21-M. Agathokleous et al.
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6.1 Nuchal translucency (NT)
The gestation should be 11–13 + 6 weeks and the fetal crown–rump length should
be 45–84 mm. Criteria for the Standardized Measurement of the Nuchal translu-
cency at 11–13 + 6 weeks are- fetus must be in the midsagittal plane. The image
must be magnified so, that it is filled by the fetal head, neck and upper thorax, the
magnification should be as large as possible and each slight movement of the
callipers should produce only a 0.1 mm change in the measurement. The fetal neck
must be in neutral position, it should not be flexed, and not hyperextended. Amnion
must be seen separate from NT line. The margins of NT edges must be clear enough
for proper placement of the callipers. (Figure 2) The + callipers on the ultrasound
must be used to perform the NT measurement. Electronic callipers must be placed
on the inner borders of the nuchal line space with none of the horizontal crossbar
itself protruding into the space and the callipers must be placed perpendicular to the
fetal long axis. Measurement must be obtained at the widest space of the NT. Cord
round the neck may be present in 5–10% of cases which may produce a falsely
increased NT. In such cases, the measurements of NT above and below the cord are
different so, the average of these two measurements should be appropriate for
calculating risk. One of the studies involving 96,127 pregnancies, at a crown rump
length of 45 mm the median and 95th centile was 1.2 and 2.1 mm and the crown
rump length of 84 mm were 1.9 and 2.7 mm [11]. The average NT in aneuploidy is
about 2.5 mm above the normal median for crown-rump length. In Turner syn-
drome, the median NT is about 8 mm above the normal median.
6.2 Nasal bone (NB)
It may be present, absent or hypoplastic. In the normal fetus between the 11th
and early 12th week of gestation, the nasal bone may appear poorly ossified or
absent [12]. In such cases, it is recommended to repeat the measurement one week
later [12]. Nasal bone hypoplasia is calculated as BPD/NBL ratio if >11 than hypo-
plasia. Several studies have demonstrated a high association between absent nasal
bone at 11–13 + 6 weeks and trisomy 21, as well as other chromosomal abnormalities
[13]. Criteria for the Standardized Measurement of the Nasal Bone at 11–
13 + 6 weeks are mid sagittal view of face with the magnification of the image
should be such that the fetal head and thorax occupy the whole screen. Mid sagittal
face is defined by the presence of the echogenic tip of the nose and rectangular
Figure 2.
Normal NT and nasal bone.
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shape of the palate anteriorly, the translucent diencephalon in the center, and the
nuchal membrane posteriorly. Minor deviations may cause non-visualization of the
tip of the nose and visibility of the zygomatic process of the maxilla. The ultrasound
transducer should be parallel to the direction of the nose and it should be gently
tilted from side to side to ensure that the Nasal bone is seen separate from the skin
(Figure 2). The echogenicity of NB should be greater than the overlying skin. Three
distinct lines are noted in nasal bone demonstration: the first two lines are horizon-
tal and parallel to each other where the top line represents the skin and bottom line
is the NB. Third one represents the tip of the nose. When the NB line appears as a
thin and less echogenic than the overlying skin, which suggests that the NB is not
yet ossified, and it is classified as being absent (Figure 5) [12].
6.3 Ductus venosus (DV)
Criteria for the Standardized Measurement of DV at 11–13 + 6 weeks are the
magnification of the image should be such that the fetal head and thorax should
occupy the whole screen. Right ventral mid sagittal view of fetal trunk should be
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demonstrated. Pulse doppler sample volume should be small (0.5–1.0 mm) and it
should be placed in the yellowish aliasing area. Insonation angle should be less than
30degrees [12]. The filter should be set at a low frequency (50-70 Hz). Sweep speed
should be high (2-3 cm/s) so that the waveforms are spread allowing better assess-
ment of the A wave (Figure 3). Ductus venosus shows biphasic wave form with low
pulsatility and antegrade flow in the diastolic components (a wave) throughout
cardiac cycle. Normal ductus venosus Doppler waveforms show a positive a-wave,
whereas the presence of an absent or reversed a-wave defines abnormal ductus
venosus waveforms. The presence of high pulsatility or reverse flow of the a-wave
in the first trimester increases the risk for chromosomal anomalies, cardiac defects,
and the occurrence of twin-twin transfusion syndrome in monochorianic twins.
Abnormal flow in the ductus venosus in about 80% of trisomy 21 fetuses and in
about 5% of chromosomally normal fetuses [13].
6.4 Tricuspid Valve
Color and pulsed Doppler examination across the tricuspid valve is commonly
used in the first trimester to assess for the presence of tricuspid valve regurgitation
(TR). The presence of TR in the first trimester has been associated with chromo-
somal abnormalities [14, 15]. In the first trimester, TR is found in less than 5% of
chromosomally normal fetuses, in more than 65% of fetuses with trisomy 21, and in
more than 30% of fetuses with trisomy 18 [14]. Interrogation of other cardiac valves
with color or pulsed Doppler is reserved for fetuses at risk for valve obstruction or
when a cardiac malformation is suspected. Criteria for tricuspid valve evaluation at
11–13 + 6 weeks are- image should be such that the fetal thorax occupies most of the
image (Figure 4). heart should be in apical position. Sample volume should be
2-3 mm should be positioned across the tricuspid valve with an angle should be less
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defined when regurgitation is more than half of the systole with velocity of >60 cm/s.
The sweep speed should be 2-3 cm/s so that the wave forms are widely spread for
better assessment. The tricuspid valve could be in sufficient in one or more of its
three cusps, so, therefore the sample volume should be placed across the valve at least
three times in an attempt to interrogate the complete valve [12].
6.5 Hepatic artery
It has been reported that high peak velocities in the hepatic artery are present in
the first trimester in fetuses at risk for trisomy 21.
7. Second trimester soft markers
They are absent nasal bone, Aberrant subclavian artery, ventriculomegaly,
increased Nuchal fold, Echogenic bowel loops, mild hydronephrosis, echogenic
intra cardiac foci, short femur short humerus, choroid plexus cysts, single umbilical
artery.
Major or minor abnormalities are found in about 75% of fetuses with trisomy 21
and in 10–15% of chromosomally normal fetuses. The Genetic sonogram is a
targeted ultrasound looking for major abnormalities as well as minor markers for
aneuploidy. Over the years these minor markers are being looked into and things
like widened pelvic angle sandal gap deformity is going out of favour and is getting
replaced by ARSA, pre nasal thickness and FMF angle. Absence of these markers
decreases the risk of downs by around 70–80% but does not completely rule out
Downs and hence Absence gives additional reassurance to the patient.
In first step when a soft marker is identified thoroughly search for other soft
markers and structural abnormalities. In second step calculate the risk of aneu-
ploidy based on likelihood ratios. This risk is calculated against background risk
based maternal age alone or in combination with First trimester combined screen-
ing or second trimester quadruple test.
7.1 Increased nuchal fold
In second and third trimesters of pregnancy, abnormal accumulation of fluid
behind the fetal neck can be known as nuchal cystic hygroma or nuchal edema. In
about 75% of fetuses with cystic hygroma, there is a chromosomal abnormality and,
in about 95% of cases, the abnormality is Turner syndrome. Chromosomal abnor-
malities are found in about one-third of the fetuses of nuchal edema and, in about
75% of cases, the abnormality is trisomy 21 or 18. Edema is also associated with fetal
cardiovascular and pulmonary defects, skeletal dysplasia, congenital infections and
metabolic and haematological disorders; The positive LR is 23.3 and negative LR is
0.8. Nuchal index is considered by some, because this is associated with gestational
age. Nuchal index is (mean nuchal fold/mean BPD) x100 where the value of 11 or
greater has a sensitivity of 50% and specificity of 96% (Figure 6).
7.2 Aberrant right subclavian artery (ARSA)
occurs in 0.5to 1.4%. four vessels arise from the aortic arch where the right
subclavian artery arises from distal part of the aortic arch and courses behind the
oesophagus and trachea to the right upper arm (Figure 7). ARSA is present in 1% of
euploid fetuses and 24% of trisomy 21. ARSA is associated with other conotruncal
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anomalies increases the risk of microdeletion 22Q11 and other syndromes. The
positive LR is 21.5 and negative LR is 0.71. when it is isolated LR is 3.9 times.
7.3 Echogenic bowel loop
This may be due to Swallowed blood, Cystic fibrosis or maternal infections. It
may be also associated with congenital malformations of the bowel more so of upper
GI lesions. And other perinatal complications, including fetal growth restriction.
We have to also look for Ascites and bowel dilatation. Diagnosis of echogenic bowel
should be confirmed by low frequency transducer, reduced Gain and without use of
harmonics. Echogenicity should be equal to or more than bone (Figure 8). Grade 2
similar to bone echogenicity Grade 3 is more than bone. The positive LR of this is
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7.4 Short femur/short Humerus
Short Femur and humerus is when the measurement is below 5th percentile for
gestational age or measured/expected ratio < 0.9. The positive LR is 3.72 and
negative LR is 0.8. regarding short humerus is the humerus measuring <2.5% or
measured/expected ratio < 0.89. The Positive LR is 4.81 and negative LR is 0.74.
7.5 Echogenic intracardiac focus (EICF)
usually noted at region of papillary muscle 88% in Lt ventricle, 5%in rt. ventricle
and 7% in biventricular. The echogenicity should be comparable to bone. Grading of
EICF - Grade 2 similar echogenicity of bone and grade 3 more denser than bone
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with aneuploidy, when compared to solitary LV EICF. The positive LR is 5.83 and
negative LR is 0.8.
7.6 Mild ventriculomegaly
Normal ventricular measurements are <10 mm. If it is defined as mild
ventriculomegaly when measurement is between 10 and 15 mm. (Figure 10). The
overall prevalence of chromosomal defects in fetal ventriculomegaly is about 10%
and the commonest chromosomal defects are trisomies 21, 18, 13 and triploidy. The
positive LR is 27.52and negative LR is0.94.
7.7 Mild hydronephrosis
pelvic AP diameter measuring >4 mm and it should be measured in transverse
section in 12 clock or 6 clock position. The positive LR is 7.6 and negative LR is 0.92
(Figure 11).
There are other soft markers also those doesn’t have any likely hood ratio but
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protocol. They are the choroid plexus cysts and single umbilical artery, sandal gap
toes, short ears, clinodactyly, increased iliac angle. Not only this Duodenal atresia
and small membranous VSD (Figure 12) is also be associated with aneuploidy [16].
7.8 Choroid plexus cysts
they may be round or oval. May be unilateral or bilateral. They may be large or
small. Commonly seen between 16 and 21 weeks by 23 week start undergoing
regression. After 25–26 weeks uncommon to see. More commonly associated with
trisomy 18. LR for trisomy 18 when isolated is 1.1–1.5.
7.9 Single umbilical artery
No strong association with aneuploidy. Usually associated with fetal cardiac,
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7.10 Pre nasal thickness
In normal fetuses, the pre nasal thickness is small and the nasal bone is relatively
long, resulting in a ratio of approximately 0.6. [17] In trisomy 21 fetuses in the first
trimester, the prenasal thickness increases, whereas the nasal bone length decreases,
resulting in a ratio > 0.8 [17].
8. Non-invasive prenatal testing (NIPT)
Other names for NIPT are NIPS- non-invasive prenatal screening, cfDNA- cell
free DNA. The test is based upon the presence of fetal cell-free DNA in the maternal
circulation. Placental cell apoptosis releases into the maternal circulation as small
DNA fragments (150-200 bp) that can be detected from >7 weeks of gestation [18]. It
is estimated that about 2–20% of circulating cfDNA in the maternal circulation is fetal
in origin [18]. so, about 1 in 103–107nucleated cells in maternal blood are fetal which
can be enriched to about 1in 10–100 by techniques such as magnetic cell sorting
(MACS) or fluorescence activated cell sorting (FACS) after attachment of magneti-
cally labelled or fluorescent antibodies on to specific fetal cell surface markers. How-
ever, with the use of fluorescent in situ hybridization (FISH) and chromosome
specific DNA probes it is possible to suspect fetal trisomy by the presence of three-
signal nuclei in some of the cells of the maternal blood enriched for fetal cells. On the
basis of currently available technology, examination of fetal cells frommaternal blood
is more likely to find an application as a method for assessment of risk. The sensitivity
of NIPT is comparable to serum screening. Analysis of fetal cells from maternal blood
is both labour intensive and requires highly skilled operators whereas in biochemical
screening which is relatively easy to apply for mass population screening. The half-
life of cfDNA is short and is typically undetectable within hours after delivery [19].
the detection rate for T21 is at 99% for a false-positive rate of 0.16% [20, 21].
Detection rate for T18 is at 97% for a false-positive rate of 0.15% [20]. The use of
NIPT is rapidly expanding and is now being offered as the primary screening test in
pregnancy. Even if the NIPT test has an excellent detection rate for T21, T18, and
T13, other aneuploidies remain missed [22–24]. NIPT is a screening and not a diag-
nostic test so, caution should be used when NIPT is incorporated in the genetic
evaluation of fetal malformations. Low fetal fraction is noted in High body mass and
sampling before 10 weeks of gestation.in some laboratories fetal fraction <4% are
considered too low to report a result which is often referred as a “no call “result. NIPT
results depends on duration of gestation, number of fetuses and whether the fetus is
live or not. For confirming number, gestational age and viability needs ultrasound
examination before going for NIPT. If its low-risk population the positive predictive
value of NIPT is low. False positive in NIPT are in placental mosaicism, vanishing
Twin, maternal sex chromosome abnormality and Neoplasia. Even if NIPT is true
positive it can-not distinguishes aneuploidy derived from translocation or disjunction
type which is needed to know the recurrence risk for this again needs diagnostic test.
Not only this the women who has no call report result needs comprehensive ultra-
sound evaluation and diagnostic tests because low fetal fraction may be associated
with increased risk of aneuploidy.
9. Invasive fetal testing
1) Chorionic villous sampling should be done at 10–15 weeks. and overall fetal
loss is 1%. This test can be done trans abdominal/trans vaginal approach and this
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procedure should be done under ultrasound guidance and the sample is Trophoblast
cells. Result comes within 48–72 hrs. Randomized studies have demonstrated that
the rate of fetal loss following first-trimester transabdominal chorionic villus
sampling is the same as with second-trimester amniocentesis. There is an associa-
tion between chorionic villus sampling before 10 weeks to fetal transverse limb
abnormalities, micrognathia and microglossia. It is therefore imperative that chori-
onic villus sampling is performed only after 11 weeks by appropriately trained
operators.
2) Amniocentesis should be done at 15–20 weeks. In this we introduce needle
inside the amniotic cavity to extract the amniotic fluid. Sampling cells are
amniocytes, fetal dermal fibroblasts. Karyotype results take 7–10 days, and overall
fetal loss is 0.5%.
3) cordocentesis (per cutaneous umbilical blood sampling) which should be
done at >18-20 weeks. Under ultrasound guidance needle should be introduced into
the cord near the placental insertion. Sampling should be done from umbilical vein.
Sampling cells are fetal blood cells sampled from umbilical vein and overall fetal loss
is 1.5–3%. In a randomized study, 4,606 low-risk, healthy women, 25–34 years old,
at 14–20 weeks of gestation, were randomly allocated to amniocentesis or ultra-
sound examination alone [25]. The total fetal loss rate in the patients having
amniocentesis was 1% higher than in the controls. The study also reported that
amniocentesis was associated with an increased risk of respiratory distress syn-
drome and pneumonia. Randomized studies have demonstrated that after early
amniocentesis i.e., around 10–14 weeks of gestation the rate of fetal loss is about 2%
higher and the incidence of talipes equinovarus is 1.6% higher than the first-
trimester chorionic villus sampling or second-trimester amniocentesis. It was
apparent that amniocentesis carried a risk of miscarriage and this in conjunction
with the financial cost implications, meant that prenatal diagnosis could not be
offered to the entire pregnant population.
10. Sonographic and biochemical features of Aneuploidy
10.1 Trisomy 21
Factors that is associated with an increased risk of “Down syndrome” are higher
maternal age, a parental translocation involving chromosome 21, previous child
with T21, significant ultrasound findings and a positive screening test result. In
pregnancies with T21 fetuses, the maternal serum concentration of free β-HCG is
about twice (about 2MoM) as high and PAPP-A is reduced to half (about 0.5 MoM)
compared to euploid pregnancies. Although NT measurement alone identifies about
75–80% of T21 fetuses, the combination of NT with maternal biomarkers in the first
trimester increases the T21 detection rate to 85–95%, while keeping the false-
positive rate at 5%. AFP is decreased in T21.
In addition to NT, other sensitive first trimester ultrasound markers of T21
include absence or hypoplasia of the nasal bone (60–70%), increased impedance to
flow in the ductus venosus (about 80%), tricuspid regurgitation, cardiac
malformations (atrioventricular septal defect) with or without generalized edema,
aberrant right subclavian artery and echogenic intracardiac focus. Increased fronto
maxillary fascial angle (short maxilla in 25%), renal pylectasis and echogenic bowel
loops are also soft markers for “Down syndrome” (Table 3).
(Figures 14–18). In second trimester scan the soft markers in Trisomy 21 are
nasal hypoplasia, increased nuchal fold thickness, intracardiac echogenic foci,
echogenic bowel, hydronephrosis, shortening of the femur and more so of the
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humerus. It may also be associate with cardiac defects, duodenal atresia, sandal gap
and clinodactyly or mid-phalanx hypoplasia of the fifth finger. Trisomy 21 is found
in about 40% of cases of duodenal atresia.
Trisomy21 Trisomy18 Trisomy13 Triploidy Turner
Ventriculomegaly + + + +
Holoprocencephaly +
Choroid plexus cyst +
Dandy walker complex + +
Fascial cleft + +
micrognathia + +
Nasal hypoplasia +
Nuchal edema + + +
Cystic hygroma +
Diaphragmatic hernia + +
Cardiac defect + + + + +
Exomphalos + +
Duodenal atresia +
Esophageal atresia + +
Renal defects + + + + +





Talipes + + +
Fetal growth restriction + + +
Source: Snijders and Nicolaides 1996, Nicolaides et al. 1992.
Table 3.
Common chromosomal defects in fetuses with sonographic abnormalities [9, 26].
Figure 14.
T21 Fetus of 12 weeks 3 days showing normal NT with AFNB and Tricuspid regurgitation.
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Figure 15.
T21 fetus of 13 weeks 5 days showing increased NT with Omphalocele.
Figure 16.
T21 fetus showing Increased NT with dilated posterior fossa and reverse flow in ductus venosus.
Figure 17.
T21 with Atrioventricular septal defect with duodenal atresia(double bubble sign) and cleft lip with palate.
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10.2 Trisomy 18 and Trisomy13
Thickened NT is a common first trimester findings in Aneuploidy. In T18 and
T13, NT median values were shown to be 5.5 and 4.0 mm, respectively [16, 27].
Reduced PAPP-A value in both trisomies noted with a median value of 0.2 MoM for
T18 and 0.3 MoM for T13. Free β-HCG values are decreased whereas it is increased
in T21. In T18 and T13 median values of free β-HCG 0.2 MoM and 0.5 MoM,
respectively. T18 or T13 is often first suspected by the presence of typical ultra-
sound features, rather than by biochemical screening (Figures 19–25). single
umbilical artery is found 80% fetuses with T18 and in about 3% of chromosomally
normal fetuses [28]. There is 7fold increased risk of T18 associated with single
umbilical artery noted. Presence of megacystis After taking into account maternal
age and fetal NT the increases the likelihood for trisomy 13 or 18 by a factor of 6.7.
Presence of exomphalos in association with T18 in first trimester is 60% com-
pared about 30% at mid gestation and 15% in neonates. Trisomy 13 and Turner
syndrome are associated with tachycardia, whereas in trisomy 18 and triploidy there
is fetal bradycardia [29]. pulsatile flow in the umbilical vein is noted in 90% of
fetuses in T18 and T13 where as 25% of chromosomally normal fetuses. The preva-
lence of chromosomal defects in Dandy walker -complex is about 40%, mainly in
trisomies 18, 13 and triploidy.
Figure 18.
T21 with Absent nasal bone with EIC, ARSA and club foot.
Figure 19.
T18 12 weeks 1 day showing increased NT, absent nasal bone, cleft lip and palate and Congenital talipes
equinovarus.
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Figure 20.
T18 fetus of 15 weeks gestational age with Holoprocencephaly and radial ray abnormality.
Figure 21.
T18 fetus showing normal NT with dilated posterior fossa and single umbilical artery at 13 weeks 2 days
followup 3D at 16 weeks 4 days with vermian rotation and incread Brainstem vermian angle.
Figure 22.
Fetus of T18 showing Diaphragmatic hernia, choroid plexus cysts and bilateral rocker bottom foot at 21 weeks
5 days gestation.
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20% 0f diaphragmatic hernia is associated with chromosomal defects mainly
withTrisomy18. Heart abnormalities are found in more than 90% of fetuses with
trisomy 18 or 13 and 40% of those with trisomy 21 or Turner syndrome. 30% and 15%
Figure 23.
15 weeks 5 days fetus of T13 showing holoprocencephaly, club hands and aborted fetus showing midline cleft
with proboscis anophthalmia and bilateral club hands.
Figure 24.
Megacystits with increased NT of 12 weeks 1 day T13 fetus.
Figure 25.
15 weeks 3 days fetus showing micrognathia with polydactyly and syndactyly. In another fetus of 14 weeks
2 days 3D showing increased NT with posterior fossa dilatation and micrognathia in T13 cases.
20
Genetics and Etiology of Down Syndrome
cases of Exomphalos at mid gestation and in neonates are associated with Chromo-
somal defects, mainly trisomies 18 and 13. The prevalence of chromosomal defects
is four-times higher when the exomphalos sac contains only bowel than in cases
where the liver is included. Prenatally 20% of oesophageal atresia cases are associated
with chromosomal defects, mainly trisomy 18. Polydactyly is associated with
trisomy 13, overlapping fingers, Talipes and rocker bottom feet are associated with
trisomy 18. Usually, Trisomy 18 and triploidy are associated with moderately severe
growth restriction whereas trisomy 13, Turner syndrome with mild growth restric-
tion and in trisomy 21 growth is essentially normal [30]. In second trimester scan
Trisomy 18 is associated with strawberry-shaped head, choroid plexus cysts,
absent corpus callosum, enlarged cisterna magna, facial cleft, micrognathia, nuchal
edema, heart defects, esophageal atresia, diaphragmatic hernia and usually
exomphalos with bowel only in the sac. The other associated findings are single
umbilical artery, renal abnormalities, echogenic bowel, myelomeningocele, growth
restriction and shortening of the limbs, radial aplasia, overlapping fingers and talipes
or rocker bottom feet.
Trisomy 13 is associated with microcephaly, holoprosencephaly, facial abnor-
malities, cardiac abnormalities, exomphalos, enlarged and echogenic kidneys and
post axial polydactyly.
11. Monosomy X (turner syndrome)
NT has a median value of 7.8 mm [16] and has often been described as a cystic
hygroma (Figure 26). The occurrence of monosomy X is not related to maternal
age. Typically, lymphatic disturbances in turner syndrome are not limited to the
neck region but involve the whole body including the presence of skin edema,
hydrothorax and ascites. Generally Normal Nasal bone is present in fetuses with
monosomy X [31]. Normal maternal serum-free β-HCG (1.1 MoM) and low PAPP-A
is noted (0.49 MoM) [32]. Typical sonographic features in monosomy X includes
large nuchal cystic hygromas, generalised edema, mild pleural effusions and ascites,
cardiac abnormalities like left ventricular outflow tract obstruction, fetal tachycar-
dia and renal anomalies such as the presence of horseshoe kidneys.
Figure 26.
2 different cases of turners syndrome with generalised edema and cystic hygroma.
21
Prenatal Screening of Aneuploidies
DOI: http://dx.doi.org/10.5772/intechopen.96757
11.1 Triploidy
In triploidy, there is a complete additional haploid set of chromosomes resulting
in 69 chromosomes in each cell instead of 46 chromosomes. The additional haploid
set can be of paternal or maternal origin. The “paternal” type is called diandric
triploidy and the “maternal” type is called digynic triploidy. These two types show
different features, which can be often differentiated on ultrasound. The typical
pattern of diandric triploidy includes the presence of a normally grown fetus with
molar placenta, whereas in digynic triploidy, severe growth restriction is noted with
a small but not molar placenta. Profile of biochemistry is different in both types due
to these placental differences. Diandric triploidy is associated with increased
maternal serum-free β-HCG and mildly decreased PAPP-A and in digynic triploidy
which is associated with markedly decreased maternal serum free β-HCG and
PAPP-A. Significantly short CRL with marked difference in size between the
abdominal and head circumference, typically of more than 2 weeks of gestational
age [33] which is a pathognomonic sign of digynic triploidy (Figure 27). In second
trimester scan Triploidy where the extra set of chromosomes is paternally derived is
associated with a molar placenta and the pregnancy rarely persists beyond
20 weeks. When there is a double maternal chromosome contribution, the preg-
nancy may persist into the third trimester (Figure 27). Commonly there is mild
Figure 27.
Two fetuses of Digynic Triploidy showing short CRL with size difference in abdominal head circumference.
Figure 28.
Live fetus at 22 weeks 4 days with Molar changes in placenta in a diandric triploidy.
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ventriculomegaly, micrognathia, cardiac abnormalities, myelomeningocele, syn-
dactyly, and ‘hitch-hiker’ toe deformity (Figure 28).
12. Risk assessment in first and second trimester
The risk for trisomies in women who have had a previous fetus or child with a
trisomy is higher than the one expected on the basis of their age alone.
when we have only CRL, NT, maternal age without biochemical markers there
are calculators where we can enter these measurements, we get the risk assessment
for downs at the time of birth- Pregnancy calculators- EDD. We can do same thing
with only 2nd trimester markers without biochemical or first trimester screen
results for this we will take the LR+ value of each marker present and LR- values of
all absent markers and multiple all of these to get the LR for combination [8].
Instead if we find any soft markers we enter the same into the excel sheet
provided by [8] M. Agathokleous et al. Excel sheet for downs.
Meta- analysis of second-trimester markers for trisomy21 [8] M. Agathokleous
et al., ultrasound obstet Gynecol 2013;41:247–261.
For example:-.
when we get the measurements, we apply the same into the calculators and get
the risk assessment for downs at the time of birth. It is given as in 1 in —————.
>1in 19(high risk): offer invasive testing.
>1in 50(high risk): offer NIPT/Invasive testing.
<1in 1000(Low risk): Back to routine second trimester genetic sonogram.
1in 50-1in 999(intermediate risk): Assess NB, DV, TR and recalculate risk+/-NIPT.
New cut-of risk for downs as 1:250, borderline between 251 and 1000, and less
risk if <1:1001.
First trimester between 11 and 13 weeks 6 days scan evaluate NT, nasal bone
along with Tricuspid valve regurgitation, a wave in Ductus Venosus and other
major structural defects. Not only this detail cardiac evaluation should be done. If
there is no abnormality repeat scan at 18–22 weeks may be recommended. In the
second trimester scan look for soft markers, if there is any marker or abnormality
detailed anatomy scan and echocardiography. In case of most isolated markers
including intra cardiac echogenic focus, echogenic Bowel, mild hydronephrosis and
short femur, there is only a small effect on modifying the pre-test odds.
All these are only screening protocols they are not diagnostic so, fetal
karyotyping option is aways open to either risk groups.
Previous affected Pregnancy.
In women who had a previous pregnancy with trisomy 21, the risk of recurrence
in the subsequent pregnancy is 0.75% higher than the maternal and gestational age-
related risk for trisomy 21 at the time of testing. Recurrence is chromosome specific.
If a previous pregnancy is T21 the result will be classified as screen positive regard-
less of level of screening markers. Risk is calculated which takes account of a
women’s age at the time of her previous pregnancy with “Down syndrome” for the
risk calculation.
“Down syndrome” may be non-disjunction type (95%) where there is a recur-
rence rate of 1% where as in translocation type like (21–21) if either parent is
carrying same type of translocation then there is 100% rate of recurrence.
If there is h/o prior affected downs child screening test is not reassuring her so,
better to go for direct invasive testing if she comes at first trimester go for CVS.
In Twin gestation.
Dichorionic twin- Free β-HCG and PAPP-A levels are nearly twice as high as
singleton. Calculate the risk for each fetus based on maternal age and fetal NT. If
one fetus the NT is increased look for other markers. Detection rate is 75–80%.
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In monozygotic twins’ risk is same as singleton pregnancies.
In monochorionic twin pregnancies raised NT is an early manifestation of TTTS.
So, false positive rate will be increased. Free beta HCG and PAPP-A levels are lower
than dichorionic twin to twin transfusion syndrome as well as for chromosomal
abnormality.
Calculate the risk of each fetus based on NT, serum biochemistry and then the
average risk between the two fetuses is considered as whole.
No method is accurate for screening of fetal aneuploidy as it is in singleton
pregnancy.
Appropriate Models for aneuploidy detection:
• Age (not recommended).
• CRL & NIPT (Ideal for first trimester, misses advantages of first trimester scan
and expensive)
• Age, CRL & NT (skill)
• Age & Biochemistry (poor detection rate)
• Age + CRL + Maternal factors +NT + PAPP-A + HCG (combined test)
• Age + Maternal factors + CRL + NT + Additional markers + Biochemistry
(enhanced sensitivity and low FPR but need time and skill)
• First trimester combined test + second trimester Quad (sequential or
integrated)
• First trimester Quad: Age + historical factors + PAPP-A + βHCG + PIGF +AFP
(risk for pre-eclampsia and NTD)
• First trimester Penta: Combined test + Nasal bone + AFP + DIA + PIGF (high
detection rate and low FPR).
13. Conclusion
In the economically privileged patient first trimester screening should include an
11–14 weeks complete assessment with first trimester combined screen, PIGF and
NIPT. For population screening is by combined screening. Woman with positive
screen test result should be counselled and offered the option of diagnostic testing.
Those who have a negative test results should be counselled regarding their lower
adjusted risk. Even if a woman has low risk results, she may choose diagnostic
testing later in pregnancy whenever there is fetal anomalies or markers on follow-
up sonography.
Acknowledgements
The authors wish to express thanks to all parentages involved for giving permis-
sion to collect the presented data. The authors also wish to express their thanks to
Dr. Ashok Khurana, Dr. TLN Praveen and Dr. Krishna Gopal for the source of
information.
24
Genetics and Etiology of Down Syndrome
Author details
Madhavilatha Routhu1* and Shiva Surya Varalakshmi Koneru2
1 Kakatiya Medical College, Warangal, India
2 Shiva Hospital, Warangal, India
*Address all correspondence to: madhaviradiologist@gmail.com
©2021 TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
25
Prenatal Screening of Aneuploidies
DOI: http://dx.doi.org/10.5772/intechopen.96757
References
[1] Benacerraf BR, Frigoletto FD. Soft
tissue nuchal fold in the second-
trimester fetus: standards for normal
measurements compared with those in
“Down syndrome”. Am J Obstet
Gynecol. 1987;157:1146–1149. [PubMed]
[Google Scholar]
[2]Nicolaides KH, Azar G, Byrne D,
Mansur C, Marks K. Fetal nuchal
translucency: ultrasound screening for
chromosomal defects in first trimester
of pregnancy. BMJ 1992;304:867–869.
[3] Bindra R, Heath V, Liao A,
Spencer K, Nicolaides KH. One stop
clinic for assessment of risk for trisomy
21 at 11–14 weeks: A prospective study
of 15,030 pregnancies. Ultrasound
Obstet Gynecol 2002;20:219–225.
[4] Spencer K, Spencer CE, Power M,
Dawson C, Nicolaides KH. Screening for
chromosomal abnormalities in the first
trimester using ultrasound and maternal
serum biochemistry in a one stop clinic:
A review of three years prospective
experience. BJOG 2003b;110:281–286.
[5] Cuckle HS, Malone FD, Wright D,
Porter TF, Nyberg DA, Comstock CH,
et al. Contingent screening for “Down
syndrome”—results from the Faster
trial. Prenat Diagn 2008;28:89-94.(Level
II-3).
[6] Baer RJ, Flessel MC, Jelliffe-
Pawlowski LL, Goldman S,Hudgins L,
Hull AD, et al. Detection rates for
aneuploidy by first-trimester and





[8]Meta- analysis of second-trimester
markers for trisomy21 M.Agathokleous
et al, ultrasound obstet Gynecol 2013;41:
247-261.
[9] Snijders RJM, Nicolaides KH.
Sequential screening. In: Nicolaides KH,
editor. Ultrasound markers for fetal
chromosomal defects. Carnforth, UK:
Parthenon Publishing, 1996, pp109–13.
[10] Chasen ST, Skupski DW,
McCullough LB, Chervenak FA.
Prenatal informed consent for
sonogram: the time for first-trimester
nuchal translucency has come. J
Ultrasound Med 2001;20:1147–1152.
[11] Snijders RJM, Noble P, Sebire N,
Souka A, Nicolaides KH. UKmulticentre
project on assessment of risk of trisomy
21 by maternal age and fetal nuchal
translucency thickness at 10–14 weeks
of gestation. Lancet 1998;351:343–346.
[12]Nicolaides KH. The fetal medicine
foundation. Available from: https://feta
lmedicine.org. Accessed March 1, 2017.
[13]Nicolaides KH. Nuchal translucency
and other first-trimester sonographic
markers of chromosomal abnormalities.
Am J Obstet Gynecol 2004;191:45–67.
[14] Falcon O, Faiola S, Huggon I, et al.
Fetal tricuspid regurgitation at the 11 + 0
to 13 + 6-week scan: association with
chromosomal defects and reproducibility
of the method. Ultrasound Obstet
Gynecol. 2006;27:609–612.
[15] Khalil A, Nicolaides KH. Fetal heart
defects: potential and pitfalls of first-
trimester detection. Semin Fetal
Neonatal Med. 2013;18:251–260.
[16]Nicolaides KH. Screening for fetal
aneuploidies at 11 to 13 weeks. Prenat
Diagn.2011;31:7–15.
[17]Manegold-Brauer G, Bourdil L,
Berg C, et al. Prenasal thickness to nasal
bone length ratio in normal and trisomy
21 fetuses at 11-14 weeks of gestation.
Prenat Diagn. 2015;35:1079–1084.
26
Genetics and Etiology of Down Syndrome
[18] Illanes S, Denbow M, Kailasam C,
et al. Early detection of cell-free fetal
DNA in maternal plasma. Early Hum
Dev. 2007;83:563–566.
[19] Lo YM, Zhang J, Leung TN, et al.
Rapid clearance of fetal DNA from
maternal plasma. Am J Hum Genet.
1999;64:218–224.
[20] Lo JO, Cori DF, Norton ME, et al.
Noninvasive prenatal testing. Obstet
Gynecol Surv. 2014;69:89–99.
[21]Norton ME, Jacobsson B,
Swamy GK, et al. Cell-free DNA analysis
for noninvasive examination of trisomy.
N Engl J Med. 2015;372:1589–1597.
[22] Syngelaki A, Pergament E,
Homfray T, et al. Replacing the
combined test by cellfree DNA testing
in screening for trisomies 21, 18 and 13:
impact on the diagnosis of other
chromosomal abnormalities. Fetal Diagn
Ther. 2014;35:174–184.
[23]Norton ME, Baer RJ, Wapner RJ,
et al. Cell-free DNA vs sequential
screening for the detection of fetal
chromosomal abnormalities. Am J
Obstet Gynecol.2016;214:727.e1–.e6.
[24]Wellesley D, Dolk H, Boyd PA, et al.
Rare chromosome abnormalities,
prevalence and prenatal diagnosis rates
from population-based congenital
anomaly registers in Europe. Eur J Hum
Genet. 2012;20:521–526.
[25] Tabor A, Philip J, Madsen M, Bang J,
Obel EB, Norgaard-Pedersen B.
Randomised controlled trial of genetic
amniocentesis in 4,606 low-risk women.
Lancet 1986;1:1287–1293.
[26]Nicolaides KH, Snijders RJM,
Gosden RJM, Berry C, Campbell S.
Ultrasonographically detectable markers
of fetal chromosomal abnormalities.
Lancet 1992;340:704–707.
[27] Santorum M, Wright D,
Syngelaki A, et al. Accuracy of first
trimester combined test in screening for
trisomies 21, 18 and 13. Ultrasound
Obstet Gynecol. 2016.doi:10.1002/
uog.17283.
[28] Rembouskos G, Cicero S, Longo D,
Sacchini C, Nicolaides KH. Single
Umbilical Artery at 11–14 weeks:
relation to chromosomal defects.
Ultrasound Obstet Gynecol 2003;22:
567–570.
[29] Liao AW, Snijders R, Geerts L,
Spencer K, Nicolaides KH. Fetal heart
rate in chromosomally abnormal
fetuses. Ultrasound Obstet Gynecol
2000;16:610–613.
[30]Nicolaides KH, Sebire NJ,
Snijders JM. Crown rump length in
chromosomally abnormal fetuses. In
Nicolaides KH (Ed) The 11–14-week
scan-The diagnosis of fetal
abnormalities. New York: Parthenon
Publishing, 1996, pp31–3.
[31]Wagner P, Sonek J, Hoopmann M,
et al. First-trimester screening for
trisomies 18 and 13, triploidy and
Turner syndrome by detailed early
anomaly scan. Ultrasound Obstet
Gynecol. 2016;48:446–451.
[32] Spencer K, Tul N, Nicolaides KH.
Maternal serum free beta-hCG and
PAPP-A in fetal sex chromosome
defects in the first trimester. Prenat
Diagn. 2000;20:390–394.
[33] Zalel Y, Shapiro I, Weissmann-
Brenner A, et al. Prenatal sonographic
features of triploidy at 12–16 weeks.
Prenat Diagn. 2016;36:650–655.
27
Prenatal Screening of Aneuploidies
DOI: http://dx.doi.org/10.5772/intechopen.96757
